An NGS Workflow for HCV and HIV Resistance Testing | GenomeWeb
March 02, 2017
Sponsored by
VelaDx

An NGS Workflow for HCV and HIV Resistance Testing

GenomeWebinar

Assistant Professor, Virology  University of Paris-Est-Creteil 

Chief Scientific Officer, VelaDx

This online seminar will highlights recent advances in the use of next-generation sequencing to detect drug resistance mutations in patients with HIV or HCV.

Sanger sequencing and PCR have been the standard molecular methods in clinical diagnostics for decades, but NGS is now swiftly becoming a routine method in different areas of clinical diagnostics, including treatment management for viral diseases.

Vela Diagnostics has developed an automated qPCR and NGS workflow called Sentosa for targeted sequencing of human and viral DNA. Our speakers will discuss practical examples of the use of this workflow to aid clinical decision-making and patient management.

Gerd Michel, Chief Scientific Officer of VelaDx discusses examples of how the Sentosa workflow may be applied to HIV and HCV, delivering accurate genotyping information and in the detection of drug-resistant mutations.

Christophe Rodriguez of the University of Paris-Est-Creteil, discusses how his team used this automated workflow for HCV resistance testing. His presentation outlines how deep sequencing technology shows better performance than population sequencing in direct-acting antiviral-experienced patients awaiting retreatment.

Sponsored by

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.

Mar
28
Sponsored by
Illumina

This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment. 

Mar
30
Sponsored by
SeraCare

Our roundtable of industry experts will provide an overview of the current regulatory landscape for clinical genomics tests.

Apr
13
Sponsored by
SeraCare

In this webinar, Gregory J. Tsongalis of Dartmouth Hitchcock Medical Center will discuss how his lab developed and validated a cancer hotspot assay. 

Apr
27
Sponsored by
SeraCare

This webinar is the third in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.